CEACAM5 and colorectal carcinoma: As another strategy, transgenic TCR can bind with CEA+ CRC cells, enhancing tumor recognition compared to wild-type T cells [56] In a study of three patients with metastatic CRC, targeted therapy of TCR reduced CEA levels between 74–99%, and one patient had metastasis regression.